In:
Immunotherapy, Future Medicine Ltd, Vol. 13, No. 8 ( 2021-06), p. 645-652
Kurzfassung:
Lay abstract Immunotherapy is an effective treatment option for several types of cancer. It is unclear whether a rechallenge with this treatment could be effective following its discontinuation due to disease progression, treatment toxicity or completion. This is a relevant issue as patients with metastatic cancer have few therapeutic options. Therefore, we share our clinical experience and a literature review about this topic. We report the clinical course of a patient affected by metastatic urothelial cancer whose disease responded to retreatment with immunotherapy after a previous long-term benefit from the same treatment, which was discontinued after 2 years having reached the maximum established treatment duration. We describe the different clinical scenarios of immunotherapy retreatment and factors potentially associated with a benefit from this therapeutic strategy.
Materialart:
Online-Ressource
ISSN:
1750-743X
,
1750-7448
DOI:
10.2217/imt-2021-0006
Sprache:
Englisch
Verlag:
Future Medicine Ltd
Publikationsdatum:
2021
